Dr Eggimann collaborated in several industrysponsored. clinical trials since Talk ID: year old BMI 41 Transferred for septic shock
|
|
- Prosper Jennings
- 5 years ago
- Views:
Transcription
1 Suggestions to prevent Candida infections Dr Philippe Eggimann, PD&MER Service de Médecine Intensive Adulte Anything I say can be highly biased Dr Eggimann collaborated in several industrysponsored clinical trials since DISCLOSURE Eggimann Dr Eggimann served on advisory board for and/or presented sponsored lectures for Pfizer, MSD, Astellas, Roche, Weyth-Lederle, Lilly, Medex Kenta-Biotech Talk ID: year old BMI 41 Transferred for septic shock ICU acquired sepsis D-9: cholecystectomy D-2: septic shock à duodenal perforations à laparostoma Norepinephrine Mechanical ventilation HCVV Parenteral nutrition Broad spectrum AB No antifungals à fever /chills à worsening hypotension Could it be a candidiasis? ICU: the world of infection 1,265 worldwide ICU 14,414 patients 51% with infection ( ) Epidemiology of severe Candida infections 843 Candida infections 1,265 worldwide ICU 14,414 patients 51% with infection ( ) 17% (11%-18.5%) EPIC II study Vincent JL, et al. JAMA. 2009;302: EPIC II study Vincent JL, et al. JAMA. 2009;302:
2 Epidemiology of severe Candida infections 843 Candida infections worldwide ICU patients 51% with infection ( ) Candidemia: 61 EPIC II study Kett D et al. CCM 2011; 39: Bitar D, et al. Em Infect Dis 2014; 20: Outcome of candidemia Outcome of candidemia Crude mortality 30% to 60% 2507 candidemia in Paris aera( ) Crude mortality 30% to 60% 1206 candidemia in ICU patients ( ) ICU All patients Candida spp Candida spp The French Mycosis Study Group Lortholary O et al. ICM 2014; 40: The French Mycosis Study Group Lortholary O et al. ICM 2014; 40: Outcome of candidemia Crude mortality 30% to 60% Attributable mortality 25% to 40% Attributable Candida spp Arendrup MC, et al. J Clin Microbiol. 2011;49:
3 Non candidemic invasive candidiasis Invasive Non candidemic candidiasis invasive candidiasis Clancy CJ, Nguyen MH. Clin Infect Dis. 2013;56: Adhesion colonization Exogenous Adhesion colonization Exogenous Pathology immunosuppression prematurity / bruns neutropenia / ileus Endogenous Pathology immunosuppression prematurity / bruns neutropenia / ileus Endogenous Saliva Stomach Ileon Teeth Jejunum Colon Knoke M. Mycoses. 1999;42(S1):30-4. León C, et al. Eur J Clin Microbiol Infect Dis. 2009;28: Adhesion colonization Exogenous Adhesion colonization Exogenous Pathology immunosuppression prematurity / bruns neutropenia / ileus Endogenous Pathology immunosuppression prematurity / bruns neutropenia / ileus Endogenous Physical barrier Immune barrier Chemical barrier Microbial barrier Invasion Risk factors Odds Ratio Colonization by Candida Antibiotics Central venous catheter ICU stay Neutropenia Previous surgery Renal failure Yan L, et al. Microbiol Res. 2013;168(7): Candidemia 5-10/10,000 admissions Eggimann P, et al. Lancet Infect Dis. 2003;3:
4 Pathophysiology of invasive candidiasis Pathophysiology of invasive candidiasis Candidemia Progressive colonization 25 may 21 may 16 may 12 may 12 may 27 may Candidemia +++ Non candidemic IC 0 to + Candidemia +++ Non candidemic IC + to ++ Candidemia ++ Non candidemic IC 0 to + Candidemia 0 to + Non candidemic IC +++ Pittet D, et al. Am J Med. 1991;91:256S-263S. Pittet D, et al. Ann Surg. 1994;220: Nucci M, Anaissie E. Clin Infect Dis. 2001;33: Eggimann P, Pittet D. Intensive Care Med. 2014;40: Treatment: 770 clinical studies 20 editorials 9 meta-analyses Candida-university Treatment: 770 clinical studies 20 editorials 9 meta-analyses Candida-university Guidelines? Treatment: 770 clinical studies 20 editorials 9 meta-analyses Candida-university Treatment: 770 clinical studies 20 editorials 9 meta-analyses Candida-university Guidelines? Which drug? What delay? Catheter removal? 4
5 Treatment of documented candidiasis Treatment of documented candidiasis Amphotericin B binding to ergosterol of outmembrane loss of permeability Very broad spectrum 50-90% side effects 20-40% for L-forms Echinocandins inhibition of cell wall Synthesis (fungicidal) Very broad spectrum 10-15% side effects Parenteral use only Failure rates in randomized adult studies 1994 to % 40% 30% Very broad spectrum 30-50% side effects Potential myelotoxicity 5-flucytosine inhibition of nucleic acid synthesis (Very) broad spectrum 10-20% side effects Many interractions Available for oral use Azoles inhibition (Cy P450) of ergosterol synthesis 20% 10% 0% ampho B L - ampho B ampho B + fluco flu conazole vori conazole caspo fungin mica fugin Rex NEJM 1994; Phillips CIF 1997; Mora-Duarte NEJM 02; Rex CID 03; Kullberg Lancet 05; Pappas CID 07; Kuse Lancet 07; Reboli NEJM 07 anidula fungin Treatment of documented candidiasis Treatment of documented candidiasis Pooled data from 7 randomized adult studies 1994 to 2007 IDSA Guidelines Pappas PG, et al. Clin Infect Dis. 2009;48: Andes DR, et al. Clin Infect Dis. 2012;54: Treatment of documented candidiasis Treatment of documented candidiasis 5
6 Treatment of documented candidiasis Treatment of documented candidiasis ESCMID Guidelines Cornely OA, et al. Clin Microbiol Infect. 2012;18: ESCMID Guidelines Cornely OA, et al. Clin Microbiol Infect. 2012;18: Treatment: 770 clinical studies 20 editorials 9 meta-analyses Which drug? What delay? Catheter removal? Candida-university Treatment of documented candidiasis Impact of delayed antifungal treatment Early treatment should be empirical!!! Nolla-Salas J, et al. Intensive Care Med. 1997;23: Morrell M, et al. Antimicrob Agents Chemother. 2005;49: Garey KW, et al. Clin Infect Dis. 2006;43: Hsu DI, et al. J Antimicrob Chemother. 2010;65: Candidemia: catheter removal? Treatment: 770 clinical studies 20 editorials 9 meta-analyses Candida-university 2 pooled studies: 1109 candidemia mortality Which drug? What delay? Catheter removal? Horn DL, et al. Eur J Clin Microbiol Infect Dis. 2010;29:
7 Candidemia: catheter removal? 2 pooled studies: 842 candidemia Candidemia: catheter removal? Swiss fungal network : 566 candidemia hospital mortality 232 (41%) attributable mortality 45 ( 8%) OR for death CVC retained : 4.07 ( ) antifungals> 72 h : 1.41 ( ) Nucci M, et al. Clin Infect Dis. 2011;51: Erard V, et al. 50th ICAAC 2010 Candidemia: catheter removal? Candidemia: catheter removal? 7 pooled studies: 1915 candidemia CVC retained CVC removed * * *P>0.01 * Andes DR, et al. Clin Infect Dis. 2012;54: ESCMID Guidelines Cornely OA, et al. Clin Microbiol Infect. 2012;18: Candidemia: catheter removal? Please, remove this catheter! Treatment: 770 clinical studies 20 editorials 9 meta-analyses Candida-university Which drug? What delay? Catheter removal? 7
8 Outcome of candidemia Antifungals in critically ill patients + Puig-Asensio M et al. Crit Care Med. 2014;42: Microbiological evidence Preemptive Prophylaxis Targeted Empirical Biomarkers Unlikely Possible Probable Proven Likelihood of disease Eggimann, Bille, Marchetti, Annals of Intensive Care 2011, 1:37 Invasive candidiasis in critically ill patients 90 % Pelz et al. Surg Infect Petri et al. Intensive Care Med Garbino et al. Intensive Care Med Nola et al. ICAAC Eggimann et al. Crit Care Med Colonized patients Infected patients 40%-80% colonized 1%-10% infected Empirical antifungal tx in critically ill patients? 40%-80% colonized 1%-10% infected? Prophylaxis?? Empirical treatment? Guidelines Preemptive treatment Prophylaxis BSAC CID 1994 yes Edwards CID 1997 data Vincent ICM 1998 SDD? Rex CID 2000 yes, but Buchner EJCMID 2002 yes at risk patients Denning Lancet ID 2003 Pappas CID 2004 carfully selected pts SFAR/SPILF/SRLF 2004 yes, but indication ESCMID 2014 yes, but carfully selected pts IDSA CID 2009/2015 yes, but carfully selected 8
9 Empirical antifungal tx in critically ill patients? Empirical antifungal tx in critically ill patients? colonized patient = infected patient 3 to 5 days Montravers P, et al. Intensive Care Med. 2013;39: Empirical antifungal tx in critically ill patients? Empirical antifungal tx in critically ill patients? 1.5% 2.5% 5.1% Very low risk Experimented clinicians failed to identify ICU patients susceptible to benefit from empirical antifungal treatment 1.9% Empirical antifungal tx in critically ill patients? Invasive candidiasis: it takes 7 to 14 days Continuous exposure to risk factors Empirical antifungal tx in critically ill patients? Invasive candidiasis: it takes 7 to 14 days Continuous exposure to risk factors Empiric antifungal treatment? Empiric antifungal treatment? Empiric antifungal treatment? Empiric antifungal treatment? Empiric antifungal treatment? Montravers P, et al. Intensive Care Med. 2013;39: Progressive colonization Pittet D, et al. Am J Med. 1991;91:256S-263S. Pittet D, et al. Ann Surg. 1994;220: Nucci M, Anaissie E. Clin Infect Dis. 2001;33: Empiric antifungal treatment? Montravers P, et al. Intensive Care Med. 2013;39: Progressive colonization Pittet D, et al. Am J Med. 1991;91:256S-263S. Pittet D, et al. Ann Surg. 1994;220: Nucci M, Anaissie E. Clin Infect Dis. 2001;33:
10 Empiric antifungal tx in critically ill patients? Colonization index Candida score Predictive rules N sites /N sites screened -Surgery on ICU admission 4th day of ICU stay: 2x weekly -Total parenteral nutrition Sepsis + CVC + Mec.Vent. >0.5 or 0.4 corrected -Severe sepsis + 1 one of: -Candida colonization -TPN (day 1-3) >2.5 points -Dialysis (day 1-3) -Major surgery (within 7days) -Pancreatitis (within 7days) -Immunosup. (within 7days) or steroids (within 7days) Start empiric antifungal treatment Patients treated: 15-20% Candidiasis captured: 85-90% Candidiasis captured : 75-85% Candidiasis captured: 60-75% Eggimann P, et al. Ann Intensive Care. 2011;1: surgical ICU patients followed over 6 months 29 colonized by Candida spp ( 3 sites nonvascular) Corrected Colonization index 0,8 0,6 0,4 0,2 Candida colonization index Documented candidia infection (n=11) Threshold reached 5-6 days before infection Does it work? Just colonized (n=18) days Pittet D, et al. Ann Surg. 1994;220: Candida colonization index Candida colonization index mixed ICU patients, ventilated for >4 days randomized to fluconazole 100 mg/d or placebo Colonization index Days P<0.05 Placebo n= candidiasis Fluconazole n=103 1 candidiasis Garbino J, et al. Intensive Care Med. 2002;28: Assessment of - the risk of invasive candidiasis: 7 studies - the value of candiduria: 5 studies - the efficacy of antifungal prophylaxis: 6 studies To guide empirical antifungal treatment: 4 studies To compare the accuracy of other markers: - Candida score 4 studies - Mannans/antimannans 2 studies - CAGTA 1 study - Betaglucans 2 studies Negative predictive value >> positive predictive value 1985 patients 714 patients 1582 patients Despite its limited bedside practicality and before confirmation of potentially more accurate predictors, such as specific biomarkers, the CI remains an important way to characterize the dynamics of colonization, which increases early in patients who develop invasive candidiasis. Eggimann P, Pittet D. Intensive Care Med. 2014;40: Empiric antifungal tx in critically ill patients? Empirical antifungal Candida tt in score critically ill patients? Colonization index Candida score Predictive rules N sites /N sites screened -Surgery on ICU admission 2x weekly -Total parenteral nutrition > 0.5 or 0.4 corrected -Severe sepsis -Candida colonization >2.5 points NPV>PPV Start empiric antifungal treatment 4th day of ICU stay: Sepsis + CVC + Mec.Vent. + 1 one of: -TPN (day 1-3) -Dialysis (day 1-3) -Major surgery (within 7days) -Pancreatitis (within 7days) -Immunosup. (within 7days) or steroids (within 7days) Patients treated: 15-20% Candidiasis captured: 85-90% Candidiasis captured : 75-85% Candidiasis captured: 60-75% Eggimann P, et al. Ann Intensive Care. 2011;1:37. Candida score > 2.5 à 7.75 (CI ) time to develop candidiasis León C, et al. Crit Care Med. 2006;34:
11 Candida score Empirical antifungal tt in critically ill patients? Empiric antifungal tx in critically ill patients? 1007 ICU patients (36 units) staying >7 days 58 candidiasis (5.8%) Colonization index Candida score Predictive rules High negative predictive value N sites /N sites screened 2x weekly > 0.5 or 0.4 corrected NPV>PPV -Surgery on ICU admission -Total parenteral nutrition -Severe sepsis -Candida colonization >2.5 points NPV>PPV 4th day of ICU stay: Sepsis + CVC + Mec.Vent. + 1 one of: -TPN (day 1-3) -Dialysis (day 1-3) -Major surgery (within 7days) -Pancreatitis (within 7days) -Immunosup. (within 7days) or steroids (within 7days) Start empiric antifungal treatment Candidiasis captured: 85-90% Patients treated: 15-20% Candidiasis captured : 75-85% Candidiasis captured: 60-75% León C, et al. Crit Care Med. 2009;37: Eggimann P, et al. Ann Intensive Care. 2011;1:37. Candida predictive rules High sentivity à High specificityà High % of patients treated with AF High % of patients missed by the rules Eggimann P, Ostrosky-Zeichner L. Curr Opin Crit Care. 2010;16: Candida predictive rules 40%-80% colonized 1%-20% infected Impossible to implement at the bedside MSG-04 (MK 0991 Protocol 067) caspofungin in high-risk patients INTENSE study micafungin in surgical patients Knitsch W et al. CID 2015? Prophylaxis?? Empirical treatment? Empiric antifungal tx in critically ill patients? Empiric antifungal tx in critically ill patients? Colonization index Candida score Predictive rules Colonization index Candida score Predictive rules N sites /N sites screened 2x weekly > 0.5 or 0.4 corrected -Surgery on ICU admission -Total parenteral nutrition -Severe sepsis -Candida colonization >2.5 points 4th day of ICU stay: Sepsis + CVC + Mec.Vent. + 1 one of: -TPN (day 1-3) -Dialysis (day 1-3) -Major surgery (within 7days) -Pancreatitis (within 7days) N sites /N sites screened 2x weekly > 0.5 or 0.4 corrected -Surgery on ICU admission -Total parenteral nutrition -Severe sepsis -Candida colonization >2.5 points 4th day of ICU stay: Sepsis + CVC + Mec.Vent. + 1 one of: -TPN (day 1-3) -Dialysis (day 1-3) -Major surgery (within 7days) -Pancreatitis (within 7days) -Immunosup. (within 7days) or steroids (within 7days) -Immunosup. (within 7days) or steroids (within 7days) NPV>PPV Start empiric antifungal treatment NPV>PPV Start empiric antifungal treatment Candidiasis captured: 85-90% Patients treated: 15-20% Candidiasis captured : 75-85% Candidiasis captured: 60-75% Candidiasis captured: 85-90% Patients treated: 15-20% Candidiasis captured : 75-85% Candidiasis captured: 60-75% Eggimann P, et al. Ann Intensive Care. 2011;1:37. Eggimann P, et al. Ann Intensive Care. 2011;1:37. 11
12 Biomarkers of candidiasis in critically ill patients Biomarkers of candidiasis in critically ill patients 95 roman ICU patients developping sepsis >5th day of stay (diag : medical 61; surgical: 12 trauma:22) Posteraro B, et al. Crit Care. 2011;15(5):R249. à 16 fungal infections à 14 invasive candidiasis à : 13 candidemia Tissot F, et al. Am J Respir Crit Care Med. 2013;188: Posteraro B, et al. Crit Care. 2011;15(5):R249. Biomarkers of candidiasis in critically ill patients 89 swiss ICU patients at very high risk of candidiasis (recurrent GI tract perforation / necrotizing pancreatitis) Biomarkers of candidiasis in critically ill patients 89 swiss ICU patients at very high risk of candidiasis (recurrent GI tract perforation / necrotizing pancreatitis) 29 invasive candidiasis Tissot F, et al. Am J Respir Crit Care Med. 2013;188: Tissot F, et al. Am J Respir Crit Care Med. 2013;188: Beta-glucan in critically ill patients 89 Swiss ICU patients at very high risk of candidiasis (recurrent GI tract perforation / necrotizing pancreatitis) The near future Tissot F, et al. ICAAC
13 A simplified approach 40%-80% colonized 1%-20% infected 1) Clinical scores à Exclude low risk patients Pratically 2) Biomarkers (betaglucan) à Start antifungals empirically? Prophylaxis?? Empirical treatment? Eggimann P, Pittet D. Intensive Care Med. 2014;40: Empiric antifungal tx in critically ill patients? Empiric antifungal tx in critically ill patients? Colonization index Candida score Predictive rules Colonization index Candida score Predictive rules N sites /N sites screened 2x weekly >0.5 or 0.4 corrected -Surgery on ICU admission -Total parenteral nutrition -Severe sepsis -Candida colonization >2.5 points 4th day of ICU stay: Sepsis + CVC + Mec.Vent. + 1 one of: -TPN (day 1-3) -Dialysis (day 1-3) -Major surgery (within 7days) -Pancreatitis (within 7days) N sites /N sites screened 2x weekly >0.5 or 0.4 corrected -Surgery on ICU admission -Total parenteral nutrition -Severe sepsis -Candida colonization >2.5 points 4th day of ICU stay: Sepsis + CVC + Mec.Vent. + 1 one of: -TPN (day 1-3) -Dialysis (day 1-3) -Major surgery (within 7days) -Pancreatitis (within 7days) Low Low -Immunosup. (within 7days) or steroids (within 7days) High High -Immunosup. (within 7days) or steroids (within 7days) Do not Start start empirical antifungal treatment treatment CONSIDER empiric antifungal treatment Candidiasis captured: 85-90% Patients treated: 15-20% Candidiasis captured : 75-85% Candidiasis captured: 60-75% Candidiasis captured: 85-90% Patients treated: 15-20% Candidiasis captured : 75-85% Candidiasis captured: 60-75% Eggimann P, et al. Ann Intensive Care. 2011;1:37. Eggimann P, et al. Ann Intensive Care. 2011;1:37. Empiric antifungal tx in critically ill patients? Empiric antifungal tx in critically ill patients? 13
14 Empiric antifungal tx in critically ill patients? Empiric antifungal tx in critically ill patients? Empiric antifungal tx in critically ill patients? To summarize Invasive candidiasis in ICU patients Thank you for your attention Do not wait until candidemia and for the invitation 14
15 15
Fungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationObjec&ves. Clinical Presenta&on
Michelle A. Barron, MD Associate Professor of Medicine Division of Infectious Diseases University of Colorado Denver Objec&ves Determine who is at risk for invasive candidiasis. Understand whether prophylaxis
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationThe EMPIRICUS trial the final nail in the coffin of empirical antifungal therapy in the intensive care unit?
Editorial The EMPIRICUS trial the final nail in the coffin of empirical antifungal therapy in the intensive care unit? Michael Osthoff 1,2, Nina Khanna 1,2, Martin Siegemund 3 1 Division of Infectious
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationWHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU?
WHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU? Empiric antifungal therapy should be considered in critically ill patients with risk factors
More informationINFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU. Claudio Viscoli Professor of Infectious Disease University of Genoa
INFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU Claudio Viscoli Professor of Infectious Disease University of Genoa What I would like to discuss with you today When to start an antifungal therapy (before
More informationTerapia della candidiasi addomaniale
Verona 16 marzo 2018 Terapia della candidiasi addomaniale Pierluigi Viale Infectious Disease Unit Teaching Hospital S. Orsola Malpighi Bologna INTRA ABDOMINAL CANDIDIASIS open questions a single definition
More informationTherapeutic Options: Where do we stand? Where do we go?
Therapeutic Options: Where do we stand? Where do we go? Oliver A. Cornely MD, FACP, FIDSA, FAAM Chair, Translational Research, CECAD Cluster of Excellence Deputy Head, Division of Infectious Diseases Director,
More informationReducing the antifungal drugs consumption in the ICU
Reducing the antifungal drugs consumption in the ICU Philippe Montravers Département d Anesthésie et Réanimation Chirurgicale CHU Bichat Claude Bernard Pole TCAUR, HUPNVS Assistance Publique-Hôpitaux de
More informationTerapia empirica e mirata delle infezioni invasive da Candida
Terapia empirica e mirata delle infezioni invasive da Candida Francesco Menichetti, MD Head, Infectious Diseases Unit Ospedale Nuovo Santa Chiara Pisa, Italy Corso Avanzato di Terapia Antibiotica X Edizione
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationSystemic Candidiasis for the clinicians: between guidelines and daily clinical practice
Systemic Candidiasis for the clinicians: between guidelines and daily clinical practice Anastasia Antoniadou Assoc. Professor Internal Medicine and Infectious Diseases National and Kapodistrian University
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationTop 5 papers in clinical mycology
Top 5 papers in clinical mycology Dirk Vogelaers Department of General Internal Medicine University Hospital Ghent Joint symposium BVIKM/BSIMC and SBMHA/BVMDM Influenza-associated aspergillosis in critically
More informationAntifungal Stewardship. Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul
Antifungal Stewardship Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul 1 2 Objectives What do we know? Invasive Candida and Aspergillosis Impact
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationLa terapia empirica nelle infezioni micotiche
La terapia empirica nelle infezioni micotiche Spinello Antinori Dipartimento di Scienze Biomediche e Cliniche Luigi Sacco Castellanza, 5 ottobre 2013 Empiric antifungal therapy: definition The receipt
More informationSupplementary Materials to the Manuscript: Polymorphisms in TNF-α Increase Susceptibility to
Supplementary Materials to the Manuscript: Polymorphisms in TNF-α Increase Susceptibility to Intra-abdominal Candida Infection in High Risk Surgical ICU Patients A. Wójtowicz, Ph.D. 1, F. Tissot, M.D.
More informationDifficult to diagnose fungal infections: Non-fungaemic candidiasis
Difficult to diagnose fungal infections: Non-fungaemic candidiasis Director, Mycology Research Unit and XDR Pathogen Laboratory University of Pittsburgh Cornelius J. Clancy, M.D. Chief, Infectious Diseases
More informationAntifungal Therapy in Leukemia Patients
Antifungal Therapy in Leukemia Patients UPDATE ECIL 4, 6 September 2011 Raoul Herbrecht, Ursula Flückiger, Bertrand Gachot, Patricia Ribaud, Anne Thiebaut, Catherine Cordonnier UPDATE ECIL 4, 2011 UPDATE
More informationWhen is failure failure?
When is failure failure? Bart-Jan Kullberg, M.D. Radboud University Nijmegen The Netherlands The ICU patient with candidemia!! Female, 39 years old!! Multiple abdominal surgeries for Crohn's disease!!
More informationTOP PAPERS in MEDICAL MYCOLOGY Laboratory Diagnosis Manuel Cuenca-Estrella Abril 2018
TOP PAPERS in MEDICAL MYCOLOGY Laboratory Diagnosis Manuel Cuenca-Estrella Abril 2018 MCE01 Conflict of interest disclosure In the past 5 years, M.C.E. has received grant support from Astellas Pharma,
More informationESCMID Online Lecture Library. by author
What is the best antifungal strategy for severe intra-abdominal infections? Philippe Montravers MD, PhD Anaesthesia and Surgical ICU Bichat Claude Bernard Hospital Assistance Publique Hopitaux de Paris
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationSolid organ transplant patients
M.6 Meet-the-expert sessions Solid organ transplant patients Martin Iversen, Denmark José M. Aguado, Spain Copenhagen, Sunday 13 October 2013 Conflict of interest disclosure In the past 5 years, J.M.A.
More informationCandida colonization index and subsequent infection in critically ill surgical patients: 20 years later
Intensive Care Med DOI 10.1007/s00134-014-3355-z MY PAPER 20 YEARS LATER Philippe Eggimann Didier Pittet Candida colonization index and subsequent infection in critically ill surgical patients: 20 years
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationOutcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei
J Antimicrob Chemother 211; 66: 375 3 doi:1.193/jac/dkq446 Advance Access publication 8 December 21 Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata
More informationFKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Clinical Infectious Diseases Advance Access published July 9, 2014 MAJOR ARTICLE FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia Nicholas D. Beyda, 1 Julie John, 1 Abdullah
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationEfficacy of a Novel Echinocandin, CD101, in a Mouse Model of Azole-Resistant Disseminated Candidiasis
Efficacy of a Novel Echinocandin, CD0, in a Mouse Model of Azole-Resistant Disseminated Candidiasis L. Miesel, K-Y Lin, J. C. Chien, M. L. Hsieh, V. Ong, and K. Bartizal Eurofins Panlabs, Taipei, Taiwan
More informationNew Directions in Invasive Fungal Disease: Therapeutic Considerations
New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman
More informationEvidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures
Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections Presenter James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University
More informationAntifungal Treatment in Neonates
Antifungal Treatment in Neonates Irja Lutsar University of Tartu, Estonia Lisbon, 12. October 2015 Prevalence of invasive fungal infections in NeoINN database 2005-2014 UK; 2012-2014 Estonia & Greece 1
More informationUse of Antifungals in the Year 2008
Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis
More informationConvegno Nazionale Terapia Antibiotica dei patogeni. Le candidemie oggi: una gestione articolata
Convegno Nazionale Terapia Antibiotica dei patogeni multiresistenti (MDRO): una sfida aperta Ferrara, 15 Giugno 2018 Le candidemie oggi: una gestione articolata Michele Bartoletti Infectious Diseases Unit
More information9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure
Faculty Overcoming Challenges in the Management of Invasive Fungal James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Departments of Pharmacy and Infectious
More informationTreatment and Prophylaxis
Treatment and Prophylaxis Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University Children s Hospital
More informationAntifungal Update. Candida: In Vitro Antifungal Susceptibility Testing
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationCandiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital
Candiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital Introduction Nosocomial bacteriuria or candiduria develops in up to 25%
More informationWhat have we learned about systemic antifungals currently available on the market?
2nd ECMM/CEMM Workshop Milano, September 25, 2010 What have we learned about systemic antifungals currently available on the market? Prof. Dr. Georg Maschmeyer Dept. of Hematology, Oncology & Palliative
More informationTitle: Author: Speciality / Division: Directorate:
Antifungal guidelines for CANDIDIASIS INFECTIONS (Adults) Proven infection: Targeted antifungal therapy should be prescribed for: o Positive cultures from a sterile site with clinical or radiological abnormality
More informationEarly Diagnosis and Therapy for Fungal Infections
Early Diagnosis and Therapy for Fungal Infections Debra Goff PharmD, FCCP Clinical Associate Professor Infectious Disease Specialist The Ohio State University Medical Center Columbus Ohio, USA The Ohio
More informationEvaluation of the predictive indices for candidemia in an adult intensive care unit
Revista da Sociedade Brasileira de Medicina Tropical 48(1):77-82, Jan-Feb, 2015 http://dx.doi.org/10.1590/0037-8682-0292-2014 Major Article Evaluation of the predictive indices for candidemia in an adult
More informationAnidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies
Received: 1 February 2017 Revised: 11 May 2017 Accepted: 11 May 2017 DOI: 10.1111/myc.12641 ORIGINAL ARTICLE Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled
More informationOutline NEW DIAGNOSTIC TOOLS WHY? WHICH TESTS? WHEN TO USE THEM? Documented IFI
New Developments and Challenges in Diagnostics of Invasive Fungal Infections O. Marchetti, MD Infectious Diseases Service, Department of Medicine, CHUV and University of Lausanne, Switzerland Workshop
More informationOptimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology
ATHENA 2017 International Conference November 28 30, 2017 Optimizing antifungal dosing regimens Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology Clinical Microbiology Laboratory, «Attikon»
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More informationRisk Factors for Mortality in Patients with Candidemia and the Usefulness of a Candida Score
Korean J Med Mycol 18(3), 2013 Original Article Risk Factors for Mortality in Patients with Candidemia and the Usefulness of a Candida Score In Ki Moon, Eun Jung Lee, Hyo Chul Kang, Shi Nae Yu, Jee Wan
More informationAntifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco 3/3 blood cultures are positive for an unidentified
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationWertigkeit der Diagnostik von Pilzinfektionen an der Intensivstation
Wertigkeit der Diagnostik von Pilzinfektionen an der Intensivstation Cornelia Lass-Flörl Division für Hygiene und medizinische Mikrobiologie MUI Innsbruck Key message... 1. Surveillance-Kulturen spielen
More informationCandidemia: Lessons learnt from Asian studies for intervention
Candidemia: Lessons learnt from Asian studies for intervention Dr Methee Chayakulkeeree Associate Professor Division of Infectious Diseases and Tropical Medicine Faculty of Medicine iriraj Hospital Mahidol
More informationLa terapia delle infezioni da Candida. Matteo Bassetti Clinica Malattie infettive A.O.U. San Martino Genova
La terapia delle infezioni da Candida Matteo Bassetti Clinica Malattie infettive A.O.U. San Martino Genova Road map Candidosi invasiva Epidemiologia Distribuzione delle specie Fattori di rischio Timing
More informationRisk Factors for IFI Length of ICU stay. Fungal Biomarkers
Fungal Biomarkers Boualem Sendid, PhD Parasitologie-Mycologie, Centre Biologie Pathologie, INSERM U995 Centre Hospitalier Régional Universitaire (CHRU), Lille, France Oscar Marchetti, MD Infectious Diseases
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationI am against to TDM in critically ill patient
TDM I am against to TDM in critically ill patient TDM of antifungals: where are we? Dr. Rafael Zaragoza Antifungal therapy in ICU; prophylaxis, pre-emptive and targeted Conflicts of interest: Pfizer Astellas
More informationAntifungal agents for preventing fungal infections in nonneutropenic critically ill patients (Review)
Antifungal agents for preventing fungal infections in nonneutropenic critically ill patients (Review) Cortegiani A, Russotto V, Maggiore A, Attanasio M, Naro AR, Raineri SM, Giarratano A This is a reprint
More informationESCMID Candida Guidelines 2011
ESCMID Candida Guidelines 2011 Andrew J. Ullmann, MD, FIDSA Universitätsmedizin III. Medizinische Klinik und Poliklinik Johannes Gutenberg-Universität, Mainz Germany Disclosure of Potential Conflicts of
More informationApproach to Fungal Infections
Approach to Fungal Infections Michelle A. Barron, M.D. Professor of Medicine Division of Infectious Diseases University of Colorado Denver Disclosures Research Investigation with Astellas Pharma, US I
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/152392
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationAntifungal susceptibility testing: Which method and when?
Antifungal susceptibility testing: Which method and when? Maiken Cavling Arendrup mad@ssi.dk SSI & Juan Luis Rodriguez Tudela jlrtudela@isciii.es ISCIII Agenda Summary of current standards and selected
More informationMicafungin, a new Echinocandin: Pediatric Development
Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationManagement of invasive candidiasis in nonneutropenic ICU patients
Therapeutic Advances in Infectious Disease Review Management of invasive candidiasis in nonneutropenic ICU patients Emmanuel Weiss and Jean-François Timsit Ther Adv Infect Dis (2014) 2(5 6) 105 115 DOI:
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationADVANCES AND CHALLENGES IN HEMATOLOGY. Invasive fungal disease management in febrile neutropenia
16 th Annual Meeting of Saudi Society of Hematology 7 th Pan Arab Hematology Association Congress ADVANCES AND CHALLENGES IN HEMATOLOGY Invasive fungal disease management in febrile neutropenia J.A. Maertens,
More informationCandida albicans 426 (64.0 ) C. albicans non-albicans
74 2006 1) 2) 1) 3) 4) 5) 6) 1) 2) 3) 4) 5) 6) 17 9 26 18 3 8 2003 10 2004 3 6 9,083 666 (7.3 ) Candida albicans 426 (64.0 ) C. albicans non-albicans 233 (35.0 ) Non-albicans Candida glabrata Candida tropicalis
More informationAntifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationMAJOR ARTICLE. (See the editorial commentary by Brass and Edwards, on pages )
MAJOR ARTICLE Early Removal of Central Venous Catheter in Patients with Candidemia Does Not Improve Outcome: Analysis of 842 Patients from 2 Randomized Clinical Trials Marcio Nucci, 1 Elias Anaissie, 2
More informationClinical Considerations in the Management of Systemic Fungal Infections. Conducted during the 41 st ASHP Midyear Clinical Meeting Anaheim, California
Clinical Considerations in the Management of Systemic Fungal Infections Conducted during the 41 st ASHP Midyear Clinical Meeting Anaheim, California CONTINUING EDUCATION ACCREDITATION The American Society
More informationOptimal Management of Invasive Aspergillosis in the Context of New Guidelines in High Risk Haematological Patients
Optimal Management of Invasive Aspergillosis in the Context of New Guidelines in High Risk Haematological Patients Shariq Haider Professor Medicine McMaster University Conflict of Interest Disclosure Slide
More informationChallenges and controversies of Invasive fungal Infections
Challenges and controversies of Invasive fungal Infections Mona Al-Dabbagh, MD, MHSc Assistant Professor of Pediatrics, COM-KSAU-HS Consultant Pediatric Infectious Diseases and Transplant Infectious Diseases
More informationClinical Study An Observational Study on Early Empiric versus Culture-Directed Antifungal Therapy in Critically Ill with Intra-Abdominal Sepsis
Critical Care Research and Practice, Article ID 479413, 8 pages http://dx.doi.org/10.1155/2014/479413 Clinical Study An Observational Study on Early Empiric versus Culture-Directed Antifungal Therapy in
More informationEmpirical Antifungal Therapy 2009 Update of ECIL-1 / ECIL-2 Guidelines O. Marchetti, C. Cordonnier, T. Calandra
UPDATE ECIL-3 2009 Empirical Antifungal Therapy 2009 Update of ECIL-1 / ECIL-2 Guidelines O. Marchetti, C. Cordonnier, T. Calandra 1 Background Empirical antifungal therapy for suspected invasive fungal
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationResearch priorities in medical mycology
Research priorities in medical mycology David W. Denning National Aspergillosis Centre University Hospital of South Manchester The University of Manchester Agenda How many patients are there with serious
More informationUpdate on Candida Infection Nov. 2010
Update on Candida Infection Nov. 2010 Gary Wong Pharmacy Clinical site leader University Health Network Course coordinator University of Toronto Goals What is an yeast infection Risk factors for yeast
More informationEpidemiology and Outcomes of Candidaemia among Adult Patients Admitted at Hospital Universiti Sains Malaysia (HUSM): A 5-Year Review
Epidemiology and Outcomes of Candidaemia among Adult Patients Admitted at Hospital Universiti Sains Malaysia (HUSM): A 5-Year Review Haydar A a a Department of Internal Medicine, Kulliyyah of Medicine,
More informationReceived 4 August 2010/Returned for modification 23 October 2010/Accepted 19 November 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2011, p. 561 566 Vol. 55, No. 2 0066-4804/11/$12.00 doi:10.1128/aac.01079-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Candida
More informationTREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS. Part I: EMPIRICAL THERAPY
TREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS Part I: EMPIRICAL THERAPY CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES NIJMEGEN, THE NETHERLANDS n = 328 BACTERIAL INFECTION FUNGAL INFECTION 7% 36%
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationFungal Infections in Patients with Severe Acute Pancreatitis and the Use of Prophylactic Therapy
MAJOR ARTICLE Fungal Infections in Patients with Severe Acute Pancreatitis and the Use of Prophylactic Therapy Jan J. De Waele, 1 D. Vogelaers, 2 S. Blot, 1 and F. Colardyn 1 1 Intensive Care Unit and
More informationInfectious Disease in the Critically Ill Patient
Infectious Disease in the Critically Ill Patient Heather L. Evans, MD MS FACS Director of Surgical Infectious Disease Harborview Medical Center Asst. Professor UW Department of Surgery New Antibiotics:
More informationPrimary prophylaxis of invasive fungal infection in patients with haematological diseases
Primary prophylaxis of invasive fungal infection in patients with haematological diseases Tunis, May 24 2012 Important questions for antifungal prophylaxis Who are the patients at risk? Which is the risk:
More informationPrevention and management of antifungal-resistant infections in the ICU
Prevention and management of antifungal-resistant infections in the ICU Adrian Brink Clinical Microbiologist, Ampath National Laboratory Services, Milpark Hospital, Johannesburg and Associate Senior Lecturer,
More informationDr Kaniz Fatema. FCPS (Medicine), MD (Critical Care Medicine) Associate Professor Dept of Critical Care Medicine BIRDEM General Hospital
Dr Kaniz Fatema FCPS (Medicine), MD (Critical Care Medicine) Associate Professor Dept of Critical Care Medicine BIRDEM General Hospital 65-years old lady HTN (15 yrs) Adult Still s Disease (2 mon)
More informationSepsis is an important issue. Clinician s decision-making capability. Guideline recommendations
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012 Clinicians decision-making capability Guideline recommendations Sepsis is an important issue 8.7%
More informationSepsi: nuove definizioni, approccio diagnostico e terapia
GIORNATA MONDIALE DELLA SEPSI DIAGNOSI E GESTIONE CLINICA DELLA SEPSI Giovedì, 13 settembre 2018 Sepsi: nuove definizioni, approccio diagnostico e terapia Nicola Petrosillo Società Italiana Terapia Antiinfettiva
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationIsavuconazole. Lepak et al 2013 Antimicrob Agents Chemother 57: Lepak et al 2013 Antimicrob Agents Chemother 57:
Priv.-Doz. Dr. med. Maria J.G.T. Vehreschild Department I of Internal Medicine Clinical Trials Unit II Infectious Diseases Research Group Clinical Microbiome Isavuconazole 09.07.2017 Maria J.G.T. Vehreschild
More informationESCMID Online Lecture Library. by author
The antibacterial experience: indications for clinical use of antimicrobial combinations To prevent the emergence of resistant organisms (tuberculosis) To treat polymicrobial infections (abdominal complicated
More informationCandida glabrata: an emerging pathogen in Brazilian tertiary care hospitals
Medical Mycology January 2013, 51, 38 44 Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals ARNALDO L. COLOMBO *, MARCIA GARNICA, LUIS FERNANDO ARANHA CAMARGO, CLOVIS ARNS DA CUNHA,
More informationCandida sake candidaemia in non-neutropenic critically ill patients: a case series
Candida sake candidaemia in non-neutropenic critically ill patients: a case series Deven Juneja, Apurba K Borah, Prashant Nasa, Omender Singh, Yash Javeri and Rohit Dang Candidaemia has been shown to be
More information